RT Journal Article
SR Electronic
T1 Hepatic resection versus transarterial chemoembolization for the intermediate stage hepatocellular carcinoma: A cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.18.20214833
DO 10.1101/2020.10.18.20214833
A1 Lu, Linbin
A1 Zheng, Peichan
A1 Wu, Zhixian
A1 Chen, Xiong
YR 2021
UL http://medrxiv.org/content/early/2021/09/21/2020.10.18.20214833.abstract
AB Background The selection criterion for hepatic resection(HR) in intermediate-stage(IM) hepatocellular carcinoma(HCC) is still controversial. We used real-world data to evaluate the overall survival (OS) treated with HR or TACE.Methods In all, 942 patients with IM-HCC were categorized in HR and TACE groups. OS was analyzed using the Kaplan-Meier method, log-rank test, Cox proportional hazards models, and propensity score- matched (PSM) analyses. The smooth curve was performed through the generalized additive model. The interaction test was performed to evaluate the HR impact on OS concerning risk factors. Also, we used multiple imputation to deal with the missing data.Results Totally, 23.0% (n=225) of patients received HR. At a median overall survival of 23.7 months, HR was associated with the improved OS on multivariate analysis (hazard ratio, 0.45; 95%CI: 0.35, 0.58; after PSM: 0.56; 95%CI: 0.41, 0.77). Landmark analyses limited to long-term survivors of ≥ 6 months, ≥ 1, and ≥ 2 years demonstrated better OS with HR in all subsets (all P<0.05). After PSM analysis, however, HR increased 20% risk of death (HR, 1.20; 95%CI: 0.67, 2.15) in the subgroup of LDH ≤192 U/L (P for interaction = 0.037). Furthermore, the significant interaction was robust between the LDH and the HR with respect to 1-, 3-, and 5-year observed survival rate (all P<0.05).Conclusion Hepatic resection was superior to TACE for intermediate-stage HCC in the range of LDH level > 192 U/L. Moreover, TACE might be suitable for patients with LDH level ≤ 192 U/L.SynopsisHepatectomy was superior to TACE for BCLC-B HCC.Hepatectomy increased 20% risk of death for LDH < 192 U/L after matching.A significant interaction was robust between LDH and with respect to hepatectomy the 1-, 3-, and 5-year observed survival rate.Competing Interest StatementThe authors have declared no competing interest.Funding StatementXiong Chen received financial support from the Natural Science Foundation of Fujian Province (Nos 2018J01352, 2016J01576, and 2016J01586); the Natural Science Foundation of 900th hospital of PLA(Nos 2016Q05 and 2017Q02 and 2017L17 and 2016L03 and 2017J03).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscriptAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol (2017-FXY-129) was approved by the department of clinical research at Sun Yat-sen University Cancer CenterAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesthe raw data were freely obtained from the Dryad Digital Repository database https://doi.org/10.5061/dryad.pd44k8r